Matrion™ Decellularized Placental Membrane in Subjects With Diabetic Foot Ulcers

Last updated: March 28, 2025
Sponsor: LifeNet Health
Overall Status: Completed

Phase

N/A

Condition

Ulcers

Diabetes And Hypertension

Treatment

Conventional Care Wound Management

Matrion

Clinical Study ID

NCT05087758
CR-21-001
  • Ages 21-80
  • All Genders

Study Summary

In this study, a novel placental membrane product Matrion™ (LifeNet Health, Inc., Virginia Beach, VA) will be used as a treatment for subjects with diabetic foot ulcers. Matrion is composed of placental membrane derived from donated human birth tissue containing both the innermost amniotic layer and the outermost chorionic layer, inclusive of the trophoblast layer. Matrion is minimally processed and disinfected using a proprietary decellularization technology and terminally sterilized that safely renders the placental membrane acellular and sterile for its intended surgical applications.

Eligibility Criteria

Inclusion

Inclusion Criteria:

To be considered eligible to participate in the study, a subject must meet the inclusion criteria listed below:

  1. Be male or female, between 21 and 80 years of age at the time of consent

  2. For subjects with a diagnosis of Type I or Type II diabetes as defined by theAmerican Diabetes Association, have been on a stable anti-diabetic treatment for atleast 30 days before the baseline visit

  3. Have a full-thickness wound of the lower extremity

  4. Have a single target ulcer

  5. Have a wound with an area greater than or equal to 1 cm2 and less than 25 cm2 and adepth less than or equal to 9 mm

  6. Have a diabetic foot ulcer that has been present for at least 30 days with a WagnerClassification Grade 1 or 2:

  • Grade 1: superficial diabetic ulcer including the full skin thickness but notunderlying tissue

  • Grade 2: ulcer extension involving ligament, tendon, joint capsule, or fascia,without presence of abscess of osteomyelitis

  1. Have an absence of infection based on Infectious Disease Society of America criteria

  2. Have an adequate circulation to the affected lower extremity, defined as at leastone these criteria:

  • Transcutaneous oxygen measurement at the dorsum of the foot greater or equal to 30 mmHg

  • Ankle-brachial index (ABI) greater than 0.75

  • At least biphasic Doppler arterial waveforms at the dorsalis pedis andposterior tibial arteries

  1. Have the ability to comply with off-loading (if required for specific wound) anddressing change requirements

  2. Have the ability to understand the requirements of the study, have provided writteninformed consent as evidenced by signature on an informed consent form (ICF)approved by an institutional review board (IRB), and agree to abide by the studyrestrictions and return to the site for the required assessments

  3. Have provided written authorization for use and disclosure of protected healthinformation

  4. Have a life expectancy of greater than 6 months

Exclusion

Exclusion Criteria:

To be eligible for entry into the study, the subject must not meet any of the exclusion criteria listed below:

  1. Be pregnant or lactating

  2. Have a wound that decreased in size ≥50% between the Screening and Baseline Visits

  3. Have circulating hemoglobin A1c exceeding 12% within 90 days of the Screening Visit

  4. Have serum creatinine concentrations of 3.0 mg/dL or greater within 30 days prior toscreening

  5. Have a sensitivity to any of the following antibiotics: Lincomycin, Polymyxin BSulfate, and/or Vancomycin

  6. Have a sensitivity to N-Lauroyl Sarcosinate, and/or Benzonase® or Denarase®

  7. Have the wound treated with biomedical or topical growth factors within the previous 30 days before the screening visit

  8. Need for any additional concomitant dressing material other than the ones approvedfor this study

  9. Have clinical signs of an infection at the study ulcer site

  10. Have the inability to tolerate off-loading (a surgical shoe, removable cast walkeror a total contact cast)

  11. Have a known or suspected disease of the immune system

  12. Have an active or untreated malignancy or active, uncontrolled connective tissuedisease

  13. Had a treatment with immunosuppressive or chemotherapeutic agents, radiotherapy orsystemic corticosteroids less than 30 days before the baseline visit

  14. Have presence of necrosis, purulence, or sinus tracts that cannot be removed bydebridement

  15. Has undergone a revascularization procedure aimed at increasing blood flow in thetreatment target limb less than 4 weeks before the baseline visit

  16. Have serum aspartate aminotransferase, alanine aminotransferase, or alkalinephosphatase levels greater than three times the normal upper limit within 30 daysprior to screening

  17. Have evidence of active Charcot disease

  18. Have undergone treatment with a living skin equivalent within the last 4 weeksbefore screening

  19. Have ongoing evidence of peripheral vascular disease, including greater than onenonpalpable pulse on either foot

  20. Have the presence of any condition that in the opinion of the investigator placesthe subject at undue risk or potentially jeopardizes the quality of the data to begenerated

Study Design

Total Participants: 108
Treatment Group(s): 2
Primary Treatment: Conventional Care Wound Management
Phase:
Study Start date:
March 01, 2022
Estimated Completion Date:
February 28, 2025

Connect with a study center

  • Compass Medical Research Center, LLC

    Tucson, Arizona 85715
    United States

    Site Not Available

  • Center for Clinical Research, INC

    Carmichael, California 95608
    United States

    Site Not Available

  • Limb Preservation Platform, INC

    Fresno, California 93710
    United States

    Site Not Available

  • ILD Research Center

    San Diego, California 92130
    United States

    Site Not Available

  • Center for Clinical Research, INC

    San Francisco, California 94115
    United States

    Site Not Available

  • Doctors Research Network

    Miami, Florida 33143
    United States

    Site Not Available

  • Albuquerque Associated Podiatrists

    Albuquerque, New Mexico 87111
    United States

    Site Not Available

  • Purvis-Moyer Foot and Ankle Center

    Rocky Mount, North Carolina 27804
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.